^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IKZF3 overexpression

    i
    Other names: IKZF3, IKAROS Family Zinc Finger 3, Zinc Finger Protein, Subfamily 1A, 3 (Aiolos), Zinc Finger Protein Aiolos, ZNFN1A3, Zinc Finger DNA Binding Protein Aiolos, IKAROS Family Zinc Finger 3 (Aiolos), Ikaros Family Zinc Finger Protein 3, AIOLOS, AIO
    Entrez ID:
    22806
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    7ms
    Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma. (PubMed, Cancers (Basel))
    Importantly, combining IMiD treatment and BRD9 targeting, which leads to the downregulation of MYC protein and upregulation of CRBN protein, was able to override IMiD resistance of cells exposed to iberdomide in long-term culture. Taken together, our results support the notion that combination therapy based on agents targeting BRD9 and IKZF3, two established dependencies in MM, represents a promising novel therapeutic strategy for MM and IMiD-resistant disease.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    IKZF3 overexpression
    |
    iberdomide (CC-220)